VYNE Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$55.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| YB-101 Phase 2a (Part 1) Topline Readout | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
YB-101 Phase 2a/2b Graves' Disease Trial Initiation QuarterlyTarget: Initiation of combined Phase 2a/2b trial in Graves' disease
Combined Company Cash Balance Quarterly24.9MTarget: Approximately $200 million post-merger and pre-closing financing
Pre-Closing Cash Dividend to Legacy VYNE Shareholders QuarterlyTarget: $14.5 million to $16.5 million ($0.34 to $0.38 per share)
Watch Items
- Completion of Reverse Merger with Yarrow BioscienceTrigger: Shareholder vote and regulatory approval of Form S-4Action: Monitor SEC filings for the closing announcement and transition to ticker YARW
- YB-101 Phase 2a (Part 1) Topline ReadoutTrigger: H2 2027 timelineAction: Evaluate percent euthyroid and off anti-thyroid drugs (ATD) clinical endpoints
- GenSci Phase 1 MAD Trial in Thyroid Eye Disease (TED) in ChinaTrigger: H2 2027 timelineAction: Assess safety, tolerability, and clinical improvements in TED endpoints
Research as of 20 Jun 2026